Clinical Trials
Investigators test combination therapy for head and neck squamous cell carcinoma in new trial
Patients with recurrent head and neck squamous cell carcinoma (HNSCC) may be eligible to participate in a new clinical trial at the NIH Clinical Center. This trial tests a therapy of a novel radiosensitizer, birinapant, in combination with radiotherapy for patients whose HNSCC has come back at or near the place of the original tumor.
Read More
Clinical trial tests a new drug therapy for recurrent ependymomas of the brain and spinal cord
Ependymomas are rare tumors that arise in the ependyma, the thin membrane that lines fluid-filled cavities in the brain and spinal cord, and there are limited treatment options for those that have already been treated with standard therapies. A new clinical trial is testing a drug that targets ependymomas that have a specific genetic signature.
Read More
Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer
Prostate cancer (PC) is the most common malignancy in American men. There is increasing evidence that there may be a link between PC and men who have a family history of ovarian or breast cancer. As researchers have learned more about the role of genetics in PC, they have taken a new approach to screening for the disease—targeting men whose genetic profiles put them at risk for developing PC.
Read More
Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer
A new clinical trial at the NCI’s Center for Cancer Research is set to explore if eliminating certain bacteria in the gut will boost the immune system response in patients who have hepatocellular carcinoma and liver metastases.
Read More
New clinical trial tests radiotracer for improved imaging of metastatic prostate cancer
Most forms of prostate cancer have receptors for prostate-specific membrane antigen (PSMA), a protein that helps fuel the development of prostate cancer cells. Investigators are studying if a radiotracer that binds to PSMA may improve imaging methods to find sites of metastatic prostate cancer.
Read More
Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects
Urothelial carcinoma (UC), or bladder cancer, is the most common cancer of the urinary tract with limited treatment options. A new clinical trial aims to see how this type of cancer reacts to olaparib, a drug designed to target cancers that have defective DNA-repair mechanisms in their cells by inhibiting the action of PARP, an enzyme that can repair breaks in DNA.
Read More
New study delivers chemotherapy to the liver for metastatic colorectal cancer patients
In some patients, colorectal cancer spreads only to the liver. Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center.
Read More
New clinical trial will determine if gliomas respond to immunotherapy
Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas.
Read More
Trial results show that younger lymphoma patients respond well to ibrutinib
A recent clinical trial using the drug ibrutinib reveals that patients under age 60 with diffuse large B-cell lymphoma are much more likely to tolerate the drug – and respond to it – compared to those age 60 and older.
Read More
New clinical trial recruits the immune system to attack chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is cancer that develops in blood-forming cells in the bone marrow. A new clinical trial is testing a way to boost the body’s natural immune cells and recruit them to attack and kill marked leukemia cells.
Read More